Evaluacíon de la actividad biológica in vitro de factores extracelulares de Lactobacillus acidophilus y Bifidobacterium longum sobre línea celular HT-29 de cáncer de colon humano.

Los probióticos son organismos vivos que cuando se administran en cantidades adecuadas ejercen un efecto benéfico para la salud del huésped. Se ha demostrado que varias cepas probióticas ejercen efectos benéficos tanto en la microbiota endógena como en el epitelio y el sistema inmune intestinal. Como microorganismos probióticos se utilizan los géneros Lactobacillus y Bifidobacterium. Hay datos que indican que los probióticos pueden impedir o retrasar la aparición de ciertos tipos de cáncer. Varios trabajos in vivo e in vitro han demostrado que probióticos detoxifican y tienen propiedad antimutagénica. Se ha demostrado en algunos trabajos in vitro que los factores extracelulares han presentado actividad biológica sobre protozoarios y bacterias de importancia médica, es por esto que en este trabajo se obtuvieron factores extracelulares de Lactobacillus acidophilus y Bifidobacterium longum para determinar la actividad biológica sobre la línea tumoral HT-29. Con los factores extracelulares, a diferentes dosis, se observó una marcada inhibición del crecimiento de HT-29, siendo las mejores concentraciones las de 13mg/mL y 26mg/mL. Se concluye que los factores extracelulares si inhiben el crecimiento de HT-29 y esto puede generar más experimentos in vitro e in vivo para demostrar la actividad antagonista de probióticos en células de cáncer

Identification of circadian-related gene expression profiles in entrained breast cancer cell lines

<p>Cancer cells have broken circadian clocks when compared to their normal tissue counterparts. Moreover, it has been shown in breast cancer that disruption of common circadian oscillations is associated with a more negative prognosis. Numerous studies, focused on canonical circadian genes in breast cancer cell lines, have suggested that there are no mRNA circadian-like oscillations. Nevertheless, cancer cell lines have not been extensively characterized and it is unknown to what extent the circadian oscillations are disrupted. We have chosen representative non-cancerous and cancerous breast cell lines (MCF-10A, MCF-7, ZR-75-30, MDA-MB-231 and HCC-1954) in order to determine the degree to which the circadian clock is damaged. We used serum shock to synchronize the circadian clocks in culture. Our aim was to initially observe the time course of gene expression using cDNA microarrays in the non-cancerous MCF-10A and the cancerous MCF-7 cells for screening and then to characterize specific genes in other cell lines. We used a cosine function to select highly correlated profiles. Some of the identified genes were validated by quantitative polymerase chain reaction (qPCR) and further evaluated in the other breast cancer cell lines. Interestingly, we observed that breast cancer and non-cancerous cultured cells are able to generate specific circadian expression profiles in response to the serum shock. The rhythmic genes, suggested via microarray and measured in each particular subtype, suggest that each breast cancer cell type responds differently to the circadian synchronization. Future results could identify circadian-like genes that are altered in breast cancer and non-cancerous cells, which can be used to propose novel treatments. Breast cell lines are potential models for <i>in vitro</i> studies of circadian clocks and clock-controlled pathways.</p

Antimicrobial and Antiinflammatory Potential of the Swedish Herbs Extract

Oral conditions that produce the greatest damage on individuals are cavities and periodontal disease, hence non-expensive and effective solutions are immediately required, particularly for communities with no access to dental services. The antimicrobial and anti-inflammatory potential of the Swedish bitter herbal extract was evaluated, using pure microbial cultures and clinical samples of 29 patients. It was observed that the extract caused significant (p<0.05) in vitro growth inhibition of up to 29%, 17%, 15%, and 50% against Prevotella intermedia, Bacteroides forsythus, Porphyromonas gingivalis and Streptococcus intermedius, respectively. In addition, the extract significantly (p<0.05) inhibited oral flora growth in patient samples showing MICs of < 7.8 μg/ml in 21% of the patients, 15.6μg/ml in 17% of the patients, 31.2 μg/ml in 10% of the patients, 62.5 μg/ml in 17% of the patients, 125 μg/ml in 3% of the patients, and 250 μg/ml in 7% of the patients, and induced a maximum of 75% growth inhibition, as measured by the MTT reduction assay. The extract was also observed to significantly suppress production of the inflammatory marker nitric oxide by LPS-treated murine peritoneal macrophages. The Swedish herbal extract may be considered in the clinics to prevent or treat bacterial oral infections and at the same time reducing inflammation

Local injection of autologous bone marrow cells to regenerate muscle in patients with traumatic brachial plexus injury

OBJECTIVES: Traumatic brachial plexus injury causes severe functional impairment of the arm. Elbow flexion is often affected. Nerve surgery or tendon transfers provide the only means to obtain improved elbow flexion. Unfortunately, the functionality of the arm often remains insufficient. Stem cell therapy could potentially improve muscle strength and avoid muscle-tendon transfer. This pilot study assesses the safety and regenerative potential of autologous bone marrow-derived mononuclear cell injection in partially denervated biceps. METHODS: Nine brachial plexus patients with insufficient elbow flexion (i.e., partial denervation) received intramuscular escalating doses of autologous bone marrow-derived mononuclear cells, combined with tendon transfers. Effect parameters included biceps biopsies, motor unit analysis on needle electromyography and computerised muscle tomography, before and after cell therapy. RESULTS: No adverse effects in vital signs, bone marrow aspiration sites, injection sites, or surgical wound were seen. After cell therapy there was a 52% decrease in muscle fibrosis (p = 0.01), an 80% increase in myofibre diameter (p = 0.007), a 50% increase in satellite cells (p = 0.045) and an 83% increase in capillary-to-myofibre ratio (p < 0.001) was shown. CT analysis demonstrated a 48% decrease in mean muscle density (p = 0.009). Motor unit analysis showed a mean increase of 36% in motor unit amplitude (p = 0.045), 22% increase in duration (p = 0.005) and 29% increase in number of phases (p = 0.002). CONCLUSIONS: Mononuclear cell injection in partly denervated muscle of brachial plexus patients is safe. The results suggest enhanced muscle reinnervation and regeneration. Cite this article: Bone Joint Res 2014;3:38–47

Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis

Introduction: Current guidelines recommend the use of anticoagulant therapy in patients with symptomatic splanchnic vein thrombosis (SVT) and suggest no routine anticoagulation in those with incidental SVT. Methods: We used the RIETE (Registro Informatizado Enfermedad Trombo Emb\uf3lica) registry to assess the rate and severity of symptomatic venous thromboembolism (VTE) recurrences and major bleeding events appearing during the course of anticoagulation in patients with symptomatic or incidental SVT. Results: In March 2017, 521 patients with SVT were recruited. Of them, 212 (41%) presented with symptomatic SVT and 309 had incidental SVT. Most (93%) patients received anticoagulant therapy (median, 147 days). During the course of anticoagulation, 20 patients developed symptomatic VTE recurrences (none died) and 26 had major bleeding (fatal bleeding, 5). On multivariable analysis, patients with incidental SVT had a non-significantly higher risk for symptomatic VTE recurrences (adjusted hazard ratio [HR]: 2.04; 95%CI: 0.71\u20135.88) and a similar risk for major bleeding (HR: 1.12; 95%CI: 0.47\u20132.63) than those with symptomatic SVT. Active cancer was associated with at increased risk for VTE recurrences (HR: 3.06; 95%CI: 1.14\u20138.17) and anaemia (HR: 4.11; 95%CI: 1.45\u201311.6) or abnormal prothrombin time (HR: 4.10; 95%CI: 1.68\u201310.1) were associated with at increased risk for major bleeding. Conclusions: The rates of recurrent SVT and major bleeding were similar between patients with incidental or symptomatic SVT. Because the severity of bleeding complications during anticoagulation may outweigh the severity of VTE recurrences in both groups, further studies should identify those SVT patients who benefit from anticoagulant therapy